<DOC>
	<DOCNO>NCT02557490</DOCNO>
	<brief_summary>The purpose study randomize control trial compare effect oxaliplatin raltitrexed treatment colorectal cancer liver metastases TACE hepatic artery infusion</brief_summary>
	<brief_title>Oxaliplatin Raltitrexed Treatment Colorectal Cancer With Liver Metastases</brief_title>
	<detailed_description>Colorectal cancer one common malignancy , 1 million new case half million death year worldwide . The development metastases main cause death . Liver metastases diagnose 10-25 % patient time resection primary colorectal tumor , eventually , 70 % patient colorectal cancer develop liver metastases.Oxaliplatin raltitrexed use treatment colorectal cancer liver metastasis . We aim perform randomize controlled trial compare effect oxaliplatin raltitrexed treatment colorectal cancer liver metastases TACE hepatic artery infusion .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>1 . With write informed consent 2 . Age range 18 80 year , men woman 3 . Confirmed pathology clinical diagnosis unresectable colorectal cancer liver metastases patient ( include primary tumor liver patient brain metastasis except outside metastasis patient unresectable ) 4 . Progress systemic chemotherapy tolerate chemotherapy , refuse chemotherapy 5 . Never receive TACE treatment 6 . ( M ) RECIST 1.0 criterion measurable liver lesion several ≥2 , lesion diameter ≥3 cm long ≤20cm , 7 . ECOG PS score ≤2 8. expect survival time ≥12 week 9 . The test result 7 day enter group must meet following requirement : Hemoglobin ≥ 90 g / L Absolute neutrophil count ( ANC ) &gt; 1,500 / mm3 Platelet count ≥ 80x109 / L Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 time upper limit normal ( UNL ) Total bilirubin &lt; 3UNL Serum creatinine &lt; 1.5 UNL PT INR , PPT &lt; 1.5 UNL ( patient undergo warfarin heparin anticoagulant therapy , evidence abnormality parameter , enter group , must closely monitored detect least week INR stable ) Exclusion criterion 1 . Specific circumstance patient suitable TACE therapy / chemotherapy 2 . Hepatic decompensation , presence hepatic encephalopathy 3 . Before enter study gastrointestinal bleeding within 30 day 4 . Presence brain metastasis 5 . Pregnant lactate woman 6 . Active bleed sepsis 7 . History heart disease : NYHA two congestive heart failure , symptomatic coronary artery disease Need use βblockers digoxin medication arrhythmias 8 . Despite treatment , still systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg hypertension 9 . Not cure severe trauma , acute incurable ulcer , three month fracture 10 . The researcher believe poor compliance 11 . Exist primary lesion histologically different tumor colorectal cancer , except : head neck carcinoma situ , cure basal cell carcinoma , superficial bladder cancer ( Ta , Tis , T1 ) , group 3 year ago , cure cancer 12 . HIV infection presence AIDSrelated illness , severe acute chronic diseases 13 . Drug abuse , suffer could interfere study compliance psychological psychiatric disorder 14 . Need drug therapy epilepsy ( steroids antiepileptic drug 15 . Chemotherapy contraindication exist 16 . Any instability likely endanger patient study safety compliance case</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>TACE ; hepatic artery infusion ; oxaliplatin ; raltitrexed</keyword>
</DOC>